西尼莫德对继发进展型多发性硬化认知功能的影响:EXPAND 二次分析
EXPAND 研究纳入 1,651 例继发进展型多发性硬化患者,随机接受西尼莫德 2 mg/d 或安慰剂。事后分析显示,西尼莫德组 SDMT 评分较基线改善在第 12、18、24 个月显著优于安慰剂组,且 SDMT 持续下降 ≥4 分的风险更低、持续升高 ≥4 分的可能性更高,而 PASAT 和 BVMT-R 无显著差异。
要点
- 西尼莫德 2 mg/d 可显著改善 SPMS 患者 SDMT 评分,12、18、24 个月均优于安慰剂。
- 西尼莫德降低 SDMT 持续下降 ≥4 分风险(HR 0.79),提高持续升高 ≥4 分可能(HR 1.28)。
- PASAT 和 BVMT-R 评分两组无显著差异(所有 p > 0.28)。
核心结论
- 西尼莫德对继发进展型多发性硬化患者的 SDMT 评分有显著获益,且变化幅度具有临床意义。
研究设计与样本
- EXPAND 为双盲、安慰剂对照 3 期试验,1,651 例 SPMS 患者按 2:1 随机接受西尼莫德 2 mg/d 或安慰剂。
- 认知功能采用 SDMT、PASAT 和 BVMT-R 在基线、每 6 个月及治疗结束时评估。
主要发现
- SDMT 评分较基线平均变化组间差异:第 12 个月 1.08(95%CI 0.23-1.94;p=0.0132),第 18 个月 1.23(95%CI 0.25-2.21;p=0.0135),第 24 个月 2.30(95%CI 1.11-3.50;p=0.0002)。
- 西尼莫德组 SDMT 评分持续下降 4 分的风险显著更低(HR 0.79,95%CI 0.65-0.96;p=0.0157)。
- 西尼莫德组 SDMT 评分持续升高 4 分的可能性更高(HR 1.28,95%CI 1.05-1.55;p=0.0131)。
- PASAT 和 BVMT-R 评分两组间无显著差异(所有 p > 0.28)。
关键数值与推荐
- SDMT 评分变化组间差异在第 12、18、24 个月分别为 1.08、1.23、2.30 分,均显著优于安慰剂。
- SDMT 持续下降 ≥4 分风险 HR 0.79(95%CI 0.65-0.96;p=0.0157),持续升高 ≥4 分 HR 1.28(95%CI 1.05-1.55;p=0.0131)。
临床怎么用
- 对于继发进展型多发性硬化患者,西尼莫德 2 mg/d 可考虑用于延缓认知处理速度下降。
- SDMT 可作为监测西尼莫德认知获益的敏感指标,PASAT 和 BVMT-R 未见显著变化。
局限性
- 该分析为预设探索性及事后分析,证据级别为 Class II。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS), by means of a predefined exploratory and post hoc analysis of the Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) study, a randomized controlled trial comparing siponimod and placebo. METHODS: EXPAND was a double-blind, placebo-controlled phase 3 trial involving 1,651 patients with SPMS randomized (2:1) to either siponimod 2 mg/d or placebo. Cognitive function was assessed with the Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and Brief Visuospatial Memory Test-Revised (BVMT-R) administered at baseline, 6-month intervals, and end of treatment. RESULTS: Between-group differences in mean change from baseline in SDMT scores were significantly better in siponimod- vs placebo-treated patients at month 12 (difference 1.08 [95% confidence interval 0.23-1.94]; p = 0.0132), month 18 (1.23 [0.25-2.21); p = 0.0135), and month 24 (2.30 [1.11-3.50]; p = 0.0002). Siponimod-treated patients were at significantly lower risk for having a 4-point sustained decrease in SDMT score (hazard ratio [HR] 0.79 [0.65-0.96]; p = 0.0157), while their chance for having a 4-point sustained increase in SDMT score was higher (HR 1.28 [1.05-1.55]; p = 0.0131). PASAT and BVMT-R scores did not differ significantly between the 2 treatment groups (all p > 0.28). CONCLUSION: Siponimod had a significant benefit on SDMT in patients with SPMS. Siponimod-treated patients were at significantly lower risk for having a ≥4-point decrease in SDMT score and had a significantly higher chance for having a ≥4-point increase in SDMT score, a magnitude of change accepted as clinically meaningful. CLINICALTRIALSGOV IDENTIFIER: NCT01665144. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for patients with SPMS, siponimod had a significant benefit on cognitive processing speed.
引用
- Benedict RHB, Tomic D, Cree BA, et al. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. Neurology. 2020. PMID: 33328324. doi:10.1212/WNL.0000000000011275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。